About Plexium

Plexium develops a targeted protein degradation platform to find new therapies for cancer and other diseases. Plexium's platform focuses on the discovery of next-generation TPD drugs that extend beyond the limited applications of Proteolysis Targeting Chimeras (PROTACs) and cereblon imids, unraveling the boundless possibilities of true drug-like protein degraders. From molecular glues to monovalent degraders, the possibilities are endless across a wide variety of therapeutic areas.